FCGR3A and cancer: CAR-NK cell therapy can circumvent the issue of CD16a polymorphism present in NK cell ADCC as the genetically engineered CAR-NK cells recognize and target cancer cells using their antigen-specific CARs, which signal and activate NK cells through their signalling module-bearing cytoplasmic tails (32).